These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 628013)

  • 1. Immunologic control of the ascites of murine adenocarcinoma 755. I. Protection with syngeneic immune serum or lymphoid cells.
    Haagensen DE; Roloson G; Collins JJ; Wells SA; Bolognesi DP; Hansen HJ
    J Natl Cancer Inst; 1978 Jan; 60(1):131-9. PubMed ID: 628013
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic control of the ascites form of murine adenocarcinoma 755. II. Tumor immunity associated with a Friend--Moloney--Ra,scher-type virus.
    Collins JJ; Roloson G; Haagensen DE; Fischinger PJ; Wells SA; Holder W; Bolognesi DP
    J Natl Cancer Inst; 1978 Jan; 60(1):141-52. PubMed ID: 203701
    [No Abstract]   [Full Text] [Related]  

  • 3. Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors.
    Basombrío MA; Prehn RT
    Cancer Res; 1972 Nov; 32(11):2545-50. PubMed ID: 5082598
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunologic responses to a murine mammary adenocarcinoma. I. Passive transfer of immunity by sera from tumor-bearing mice.
    Yamamura Y; Virella G; Haskill JS
    Int J Cancer; 1977 May; 19(5):707-16. PubMed ID: 68018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response to a mammary adenocarcinoma. IV. Blocking of cell-mediated cytolysis by immunoglobulins binding to immune lymphocytes.
    Huber SA; Lucas ZJ
    J Immunol; 1977 Aug; 119(2):726-36. PubMed ID: 328781
    [No Abstract]   [Full Text] [Related]  

  • 6. Discussion paper: the immune status of the murine host bearing transplantable syngeneic growing tumors.
    Manson LA
    Ann N Y Acad Sci; 1976; 276():272-5. PubMed ID: 829206
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of serial transplantation on the immunological-clinical correlates of BALB/cfC3H mouse mammary tumors.
    Hager JC; Miller FR; Heppner GH
    Cancer Res; 1978 Aug; 38(8):2492-500. PubMed ID: 667845
    [No Abstract]   [Full Text] [Related]  

  • 8. Transplantation of allogeneic tumours in rats treated with antilymphocyte serum.
    Kellen JA
    Oncology; 1973; 28(5):439-44. PubMed ID: 4770464
    [No Abstract]   [Full Text] [Related]  

  • 9. Quantitative effects of nutritional protein and calorie deficiency upon immune responses to tumors in mice.
    Jose DG; Good RA
    Cancer Res; 1973 Apr; 33(4):807-12. PubMed ID: 4633154
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor immunity and the mechanism of polyinosinic-polycytidylic acid inhibition of tumor growth.
    Kreider JW; Benjamin SA
    J Natl Cancer Inst; 1972 Nov; 49(5):1303-10. PubMed ID: 4568087
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.
    Cavallo F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Modesti A; Forni G
    J Immunol; 1992 Dec; 149(11):3627-35. PubMed ID: 1358974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discussion paper: are peripheral and in situ tumor immunity related?
    Haskill JS; Yamamura Y; Radov L; Parthenais E
    Ann N Y Acad Sci; 1976; 276():373-80. PubMed ID: 1071967
    [No Abstract]   [Full Text] [Related]  

  • 13. Rejection of mammary adenocarcinoma cell tumors and the prevention of progressive growth of incipient metastases following intratumor permeation with killed Bordetella pertussis.
    Likhite VV
    Cancer Res; 1974 Oct; 34(10):2790-4. PubMed ID: 4370327
    [No Abstract]   [Full Text] [Related]  

  • 14. Rejection of murine mammary tumours in BALB/c mice.
    Robidoux S; Kajdos A; Tomana M; Niedermeier CW
    Br J Cancer; 1979 Jan; 39(1):99-100. PubMed ID: 758934
    [No Abstract]   [Full Text] [Related]  

  • 15. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
    Likhite VV
    J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune reactions of the syngeneic host after the intradermal injection of tumor cells and microsomes.
    Bertschmann M; Lüscher EF
    Adv Exp Med Biol; 1973; 29(0):513-8. PubMed ID: 4212066
    [No Abstract]   [Full Text] [Related]  

  • 17. Protective serum effects in tumor immunity.
    Vaage J
    Isr J Med Sci; 1976; 12(4-5):334-43. PubMed ID: 939693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The delayed and lasting rejection of mammary adenocarcinoma cell tumors in DBA-2 mice with use of killed Bordetella pertussis.
    Likhite VV
    Cancer Res; 1974 May; 34(5):1027-30. PubMed ID: 4363061
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune response to a mammary adenocarcinoma. VI. Blocking of tumor-specific cell-mediated cytotoxicity by antibodies to the cytotoxic lymphocyte.
    Huber SA; Lucas ZJ
    J Immunol; 1978 Dec; 121(6):2490-6. PubMed ID: 309904
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunity to a TA3 tumor subline that grows in allogeneic hosts elicited by strain-specific TA3 tumor cells.
    Lippman MM; Venditti JM; Kline I; Elam DL
    Cancer Res; 1973 Apr; 33(4):679-84. PubMed ID: 4696468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.